JP2023544592A5 - - Google Patents
Info
- Publication number
- JP2023544592A5 JP2023544592A5 JP2023520143A JP2023520143A JP2023544592A5 JP 2023544592 A5 JP2023544592 A5 JP 2023544592A5 JP 2023520143 A JP2023520143 A JP 2023520143A JP 2023520143 A JP2023520143 A JP 2023520143A JP 2023544592 A5 JP2023544592 A5 JP 2023544592A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- amino acid
- acid sequence
- seq
- ile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086674P | 2020-10-02 | 2020-10-02 | |
| US63/086,674 | 2020-10-02 | ||
| PCT/US2021/053060 WO2022072760A1 (en) | 2020-10-02 | 2021-10-01 | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023544592A JP2023544592A (ja) | 2023-10-24 |
| JP2023544592A5 true JP2023544592A5 (enExample) | 2024-10-09 |
| JP7850143B2 JP7850143B2 (ja) | 2026-04-22 |
Family
ID=78676633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520143A Active JP7850143B2 (ja) | 2020-10-02 | 2021-10-01 | Ｇ１３ｄ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｄｑ ｔ細胞受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230365649A1 (enExample) |
| EP (1) | EP4222169A1 (enExample) |
| JP (1) | JP7850143B2 (enExample) |
| KR (1) | KR20230084524A (enExample) |
| CN (1) | CN116710111A (enExample) |
| AU (1) | AU2021351710A1 (enExample) |
| CA (1) | CA3194229A1 (enExample) |
| GB (1) | GB2615010A (enExample) |
| TW (2) | TW202229327A (enExample) |
| WO (1) | WO2022072760A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4297785A4 (en) | 2021-02-26 | 2025-01-22 | New York University | COMPOSITIONS AND METHODS USING ANTIBODIES FOR BINDING TO COVALENT PEPTIDE CONJUGATES |
| WO2025056685A1 (en) * | 2023-09-15 | 2025-03-20 | Medigene Immunotherapies Gmbh | T-CELL RECEPTOR AGAINST mKRAS7-16 G12V |
| WO2026024602A2 (en) * | 2024-07-22 | 2026-01-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors against ras with g12d, g12v, g13d or q61r mutation |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| US20100286143A1 (en) * | 2009-04-24 | 2010-11-11 | Dora Dias-Santagata | Methods and materials for genetic analysis of tumors |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| US20140134158A1 (en) * | 2012-05-22 | 2014-05-15 | Alberto Bardelli | Kras mutations and resistance to anti-egfr treatment |
| CN118994363A (zh) * | 2014-11-26 | 2024-11-22 | 美国卫生和人力服务部 | 抗突变的kras的t细胞受体 |
| ES2879287T3 (es) * | 2015-09-15 | 2021-11-22 | Us Health | Receptores de células T que reconocen KRAS mutado restringido a HLA-cw8 |
| GB201608052D0 (en) * | 2016-05-09 | 2016-06-22 | Univ Oslo Hf | T-cell receptors which recognise frameshift mutants of TGF-beta RII |
| HRP20221183T1 (hr) * | 2016-08-02 | 2022-12-09 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | T-stanični receptori anti-kras-g12d |
| MX2019003768A (es) * | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| KR20250037592A (ko) * | 2017-09-20 | 2025-03-17 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 돌연변이된 ras에 대한 hla 클래스 ii-제한된 t 세포 수용체 |
| WO2019069125A1 (en) * | 2017-10-06 | 2019-04-11 | Oslo Universitetssykehus Hf | CHIMERIC ANTIGEN RECEPTORS |
| CR20200287A (es) * | 2017-12-04 | 2020-11-11 | Us Health | Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado |
| CA3094468A1 (en) * | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| MX2020014243A (es) * | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| JP2021533777A (ja) * | 2018-08-16 | 2021-12-09 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞受容体構築物およびその使用 |
| WO2020145222A1 (ja) * | 2019-01-07 | 2020-07-16 | 地方独立行政法人神奈川県立病院機構 | 新規ネオアンチゲン及びそれらを用いたがん免疫治療薬 |
| US12325734B2 (en) * | 2019-01-15 | 2025-06-10 | Altor Bioscience Llc | Human immunodeficiency virus-specific T cell receptors |
| WO2020154617A1 (en) * | 2019-01-25 | 2020-07-30 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting mutant ras |
| WO2020191365A1 (en) * | 2019-03-21 | 2020-09-24 | Gigamune, Inc. | Engineered cells expressing anti-viral t cell receptors and methods of use thereof |
| PH12021553152A1 (en) * | 2019-06-18 | 2022-08-15 | Regeneron Pharma | Mage-a4 t cell receptors and methods of use thereof |
| DE102019121007A1 (de) * | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| CN115279784A (zh) * | 2020-02-12 | 2022-11-01 | 美国卫生和人力服务部 | 针对含有g12d突变的ras的hla i类限制性t细胞受体 |
| US20230109318A1 (en) * | 2020-02-24 | 2023-04-06 | Oblique Therapeutics Ab | Kras epitopes and antibodies |
| KR20210153539A (ko) * | 2020-06-10 | 2021-12-17 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
-
2021
- 2021-10-01 TW TW110136658A patent/TW202229327A/zh unknown
- 2021-10-01 AU AU2021351710A patent/AU2021351710A1/en active Pending
- 2021-10-01 TW TW114122865A patent/TW202540156A/zh unknown
- 2021-10-01 CN CN202180072524.XA patent/CN116710111A/zh active Pending
- 2021-10-01 EP EP21810460.2A patent/EP4222169A1/en active Pending
- 2021-10-01 WO PCT/US2021/053060 patent/WO2022072760A1/en not_active Ceased
- 2021-10-01 US US18/027,981 patent/US20230365649A1/en active Pending
- 2021-10-01 CA CA3194229A patent/CA3194229A1/en active Pending
- 2021-10-01 JP JP2023520143A patent/JP7850143B2/ja active Active
- 2021-10-01 KR KR1020237014854A patent/KR20230084524A/ko active Pending
- 2021-10-01 GB GB2305617.9A patent/GB2615010A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023544592A5 (enExample) | ||
| Peruzzi et al. | Peptide sequence requirements for the recognition of HLA-B* 2705 by specific natural killer cells | |
| Trowsdale | Genomic structure and function in the MHC | |
| von Boehmer | The selection of the α, β heterodimeric T-cell receptor for antigen | |
| GB2615010A (en) | HLA class II-restricted DQ T cell receptors against RAS with G13D mutation | |
| Stroynowski et al. | Antigen presentation by non-classical class I molecules | |
| Kirberg et al. | Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. | |
| Reth | Antigen receptors on B lymphocytes | |
| Tonegawa | The molecules of the immune system | |
| Marrack et al. | Comparison of peptides bound to spleen and thymus class II. | |
| Moretta et al. | Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. | |
| GB2610311A (en) | HLA class I-restricted T cell receptors against RAS with G12V mutation | |
| Mesci et al. | NKR-P1 biology: from prototype to missing self | |
| Colonna | Natural killer cell receptors specific for MHC class I molecules | |
| van Els et al. | A single naturally processed measles virus peptide fully dominates the HLA‐A* 0201‐associated peptide display and is mutated at its anchor position in persistent viral strains | |
| Franksson et al. | Tumorigenicity conferred to lymphoma mutant by major histocompatibility complex-encoded transporter gene. | |
| GB2610069A (en) | HLA class II-restricted T cell receptors against RAS with G12V mutation | |
| JP2023527613A5 (enExample) | ||
| Sant | Endogenous antigen presentation by MHC class II molecules | |
| JP2023534241A5 (enExample) | ||
| AU2003258672A1 (en) | Method for isolating hepatitis c virus peptides | |
| JP2022523024A5 (enExample) | ||
| Kärre | Natural killer cells and the MHC class I pathway of peptide presentation | |
| JP5999703B2 (ja) | ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ | |
| McReynolds et al. | The polyprotein allergens of nematodes |